Sung Won Song
Director/Board Member bei JW (CAYMAN) THERAPEUTICS CO. LTD
Aktive Positionen von Sung Won Song
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Director/Board Member | 29.08.2023 | - |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Director/Board Member | - | - |
Karriereverlauf von Sung Won Song
Ausbildung von Sung Won Song
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The Ohio State University | Doctorate Degree |
| Korea University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| China | 3 |
| Südkorea | 2 |
Operativ
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Private Unternehmen | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
- Börse
- Insiders
- Sung Won Song
- Erfahrung
